Zhicheng Lin

List of Publications by Citations

76 papers	1,886 citations	23 h-index	41 g-index
80 ext. papers	2,290 ext. citations	6 avg, IF	4.53 L-index

#	Paper	IF	Citations
76	Weight Loss and Malnutrition in Patients with Parkinson's Disease: Current Knowledge and Future Prospects. *Frontiers in Aging Neuroscience*, **2018**, 10, 1	5.3	129
75	Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models. *Critical Reviews in Toxicology*, **2012**, 42, 613-32	5.7	119
74	Exosomes and Their Therapeutic Potentials of Stem Cells. *Stem Cells International*, **2016**, 2016, 7653489	5	105
73	VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease. *Gene Therapy*, **2011**, 18, 394-402	4	91
72	Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. *Molecular Pharmacology*, **1999**, 56, 434-47	4.3	87
71	Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference. *Scientific Reports*, **2017**, 7, 17410	4.9	81
70	Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y. *Neuroscience*, **2011**, 199, 292-302	3.9	80
69	Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson's disease. *Neurobiology of Aging*, **2012**, 33, 1777-91	5.6	77
68	Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease. *PLoS ONE*, **2009**, 4, e7878	3.7	77
67	Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. *Journal of Biological Chemistry*, **2003**, 278, 20162-70	5.4	70
66	The role of autophagy in Parkinson's disease: rotenone-based modeling. *Behavioral and Brain Functions*, **2013**, 9, 13	4.1	65
65	Restless Legs Syndrome: From Pathophysiology to Clinical Diagnosis and Management. *Frontiers in Aging Neuroscience*, **2017**, 9, 171	5.3	58
64	Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease. *PLoS ONE*, **2011**, 6, e20677	3.7	55
63	SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. *Human Molecular Genetics*, **2005**, 14, 1393-404	5.6	44
62	Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. *Cellular and Molecular Neurobiology*, **2006**, 26, 875-89	4.6	42
61	Long-term efficacy and safety of human umbilical cord mesenchymal stromal cells in rotenone-induced hemiparkinsonian rats. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 1519-29	4.7	41
60	Monoamine transporters: vulnerable and vital doorkeepers. *Progress in Molecular Biology and Translational Science*, **2011**, 98, 1-46	4	34

59	Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement. *BMC Neuroscience*, **2015**, 16, 82	3.2	33
58	Puerarin protects dopaminergic neurons in Parkinson's disease models. *Neuroscience*, **2014**, 280, 88-98	3.9	31
57	Effectiveness of traditional Chinese medicine as an adjunct therapy for Parkinson's disease: a systematic review and meta-analysis. *PLoS ONE*, **2015**, 10, e0118498	3.7	31
56	Human dopamine transporter gene variation: effects of protein coding variants V55A and V382A on expression and uptake activities. *Pharmacogenomics Journal*, **2003**, 3, 159-68	3.5	29
55	Exosomes from patients with Parkinson's disease are pathological in mice. *Journal of Molecular Medicine*, **2019**, 97, 1329-1344	5.5	27
54	Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons. *Behavioural Brain Research*, **2019**, 360, 286-297	3.4	26
53	Fenpropathrin, a Widely Used Pesticide, Causes Dopaminergic Degeneration. *Molecular Neurobiology*, **2016**, 53, 995-1008	6.2	23
52	Ventral midbrain correlation between genetic variation and expression of the dopamine transporter gene in cocaine-abusing versus non-abusing subjects. *Addiction Biology*, **2014**, 19, 122-31	4.6	23
51	Olfactory Dysfunction in Recovered Coronavirus Disease 2019 (COVID-19) Patients. *Movement Disorders*, **2020**, 35, 1100-1101	7	21
50	Genetic influences of dopamine transport gene on alcohol dependence: a pooled analysis of 13 studies with 2483 cases and 1753 controls. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2011**, 35, 1255-60	5.5	21
49	Using iPSC-derived human DA neurons from opioid-dependent subjects to study dopamine dynamics. *Brain and Behavior*, **2016**, 6, e00491	3.4	20
48	SLC6A3 is a risk factor for Parkinson's disease: a meta-analysis of sixteen years' studies. *Neuroscience Letters*, **2014**, 564, 99-104	3.3	20
47	Human genetics and pharmacology of neurotransmitter transporters. *Handbook of Experimental Pharmacology*, **2006**, 327-71	3.2	19
46	bFGF promotes the differentiation and effectiveness of human bone marrow mesenchymal stem cells in a rotenone model for Parkinson's disease. *Environmental Toxicology and Pharmacology*, **2013**, 36, 411-422	5.8	17
45	HMGB1 Mediates Autophagy Dysfunction via Perturbing Beclin1-Vps34 Complex in Dopaminergic Cell Model. *Frontiers in Molecular Neuroscience*, **2017**, 10, 13	6.1	17
44	Emerging Evidence for Neuropsycho-Consequences of COVID-19. *Current Neuropharmacology*, **2021**, 19, 92-96	7.6	17
43	Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease. *Molecular Neurobiology*, **2017**, 54, 2878-2888	6.2	16
42	High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life. *FASEB Journal*, **2010**, 24, 2191-200	0.9	15

41	A Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future Prospects. *Frontiers in Aging Neuroscience*, **2016**, 8, 117	5.3	15
40	SARS-CoV-2 positivity in a discharged COVID-19 patient: a case report. *Clinical Microbiology and Infection*, **2020**, 26, 1115-1117	9.5	12
39	Human dopamine transporter gene: differential regulation of 18-kb haplotypes. *Pharmacogenomics* , **2013**, 14, 1481-94	2.6	12
38	Tetrahydrocannabinol Increases Dopamine D1-D2 Receptor Heteromer and Elicits Phenotypic Reprogramming in Adult Primate Striatal Neurons. *IScience*, **2020**, 23, 100794	6.1	12
37	Multiple pathways for natural product treatment of Parkinson's disease: A mini review. *Phytomedicine*, **2019**, 60, 152954	6.5	11
36	Induced pluripotent stem cells and Parkinson's disease: modelling and treatment. *Cell Proliferation*, **2016**, 49, 14-26	7.9	11
35	Resilience of Alzheimer's Disease to COVID-19. *Journal of Alzheimer's Disease*, **2020**, 77, 67-73	4.3	10
34	Radiology indispensable for tracking COVID-19. *Diagnostic and Interventional Imaging*, **2021**, 102, 69-75	5.4	10
33	A case of COVID-19 pneumonia with cerebral hemorrhage. *Thrombosis Research*, **2020**, 193, 22-24	8.2	9
32	3'UTR Is a New SLC6A3 Downregulator Associated with an Epistatic Protection Against Substance Use Disorders. *Molecular Neurobiology*, **2018**, 55, 5611-5622	6.2	8
31	Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts. *Schizophrenia Bulletin*, **2016**, 42, 772-81	1.3	8
30	Genetic variants in GAPDH confer susceptibility to sporadic Parkinson's disease in a Chinese Han population. *PLoS ONE*, **2015**, 10, e0135425	3.7	8
29	hVMAT2: A Target of Individualized Medication for Parkinson's Disease. *Neurotherapeutics*, **2016**, 13, 623-34	6.4	8
28	The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease. *Cellular and Molecular Life Sciences*, **2017**, 74, 3741-3768	10.3	7
27	COVID-19 targets the right lung. *Critical Care*, **2020**, 24, 339	10.8	7
26	The correlation between DNA methylation and transcriptional expression of human dopamine transporter in cell lines. *Neuroscience Letters*, **2018**, 662, 91-97	3.3	7
25	Tobacco smoking confers risk for severe COVID-19 unexplainable by pulmonary imaging. *Journal of Internal Medicine*, **2021**, 289, 574-583	10.8	7
24	Identification of an intronic cis-acting element in the human dopamine transporter gene. *Molecular Biology Reports*, **2012**, 39, 5393-9	2.8	6

23	Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review. *Current Gene Therapy*, **2020**, 20, 285-288	4.3	6
22	Management of a Parkinson's disease patient with severe COVID-19 pneumonia. *Therapeutic Advances in Chronic Disease*, **2020**, 11, 2040622320949423	4.9	6
21	Novel Gene Mutations Identified in Patients Diagnosed with Chorea-acanthocytosis (ChAc): Case Presentation and Literature Review. *Frontiers in Aging Neuroscience*, **2017**, 9, 95	5.3	5
20	Cocaine Reduces the Neuronal Population While Upregulating Dopamine D2-Receptor-Expressing Neurons in Brain Reward Regions: Sex-Effects. *Frontiers in Pharmacology*, **2021**, 12, 624127	5.6	5
19	Invisible spread of SARS-CoV-2. *Lancet Infectious Diseases, The*, **2020**, 20, 1011-1012	25.5	4
18	Effective Chest CT-Based Diagnosis for Coronavirus Disease (COVID-19). *American Journal of Roentgenology*, **2020**, 215, W37-W38	5.4	4
17	Lower Dopamine D2 Receptor Expression Levels in Human Dopaminergic Neurons Derived From Opioid-Dependent iPSCs. *American Journal of Psychiatry*, **2016**, 173, 429-31	11.9	4
16	Severe COVID-19 in Alzheimer's disease: APOE4's fault again?. *Alzheimer's Research and Therapy*, **2021**, 13, 111	9	3
15	Intragenic Transcriptional cis-Antagonism Across SLC6A3. *Molecular Neurobiology*, **2019**, 56, 4051-4060	6.2	3
14	Involvement of CB2 Receptors in the Neurobehavioral Effects of (Vahl) Endl. (Khat) in Mice. *Molecules*, **2019**, 24,	4.8	2
13	Presence of recombination hotspots throughout SLC6A3. *PLoS ONE*, **2019**, 14, e0218129	3.7	2
12	Epistatic evidence for gender-dependant slow neurotransmission signalling in substance use disorders: PPP1R12B versus PPP1R1B. *EBioMedicine*, **2020**, 61, 103066	8.8	2
11	Next-Generation Sequencing and Proteomics of Cerebrospinal Fluid From COVID-19 Patients With Neurological Manifestations.. *Frontiers in Immunology*, **2021**, 12, 782731	8.4	2
10	Affected olfaction in COVID-19: Re-defining "asymptomatic". *EClinicalMedicine*, **2020**, 29, 100628	11.3	2
9	Mechanisms for substance use disorders in COVID-19. *Molecular Psychiatry*, **2021**, 26, 4568-4569	15.1	2
8	Identification of HIVEP2 as a dopaminergic transcription factor related to substance use disorders in rats and humans. *Translational Psychiatry*, **2019**, 9, 247	8.6	1
7	Mild manifestations of COVID-19 in healthcare workers. *PLoS Neglected Tropical Diseases*, **2020**, 14, e0008950	4.8	1
6	Postpandemic Testing of Severe Acute Respiratory Syndrome Coronavirus 2 in the Huanan Seafood Market Area in Wuhan, China. *Clinical Infectious Diseases*, **2021**, 72, 2203-2205	11.6	1

5	Modern lifestyle risks associated with alcohol consumption and cigarette smoking in Ukraine. *Journal of Substance Use*,1-6	0.8	1
4	Emergent hospital reform in response to outbreak of COVID-19. *Brain, Behavior, and Immunity*, **2020**, 88, 954-955	16.6	0
3	Alterations of white matter tracts and topological properties of structural networks in hemifacial spasm.. *NMR in Biomedicine*, **2022**, e4756	4.4	0
2	Pearson patterns correlational of clinical risks at admissions with hospitalization outcomes during initial COVID-19 outbreak. *IScience*, **2022**, 25, 104415	6.1	0
1	Feasibility of controlling COVID-19. *The Lancet Global Health*, **2020**, 8, e774	13.6	